

HALOZYME THERAPEUTICS INC

Form 4/A

June 08, 2007

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0287Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Frost Gregory Ian

(Last) (First) (Middle)

C/O HALOZYME  
THERAPEUTICS, INC., 11588  
SORRENTO VALLEY ROAD,  
SUITE 17

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
SymbolHALOZYME THERAPEUTICS  
INC [HALO]3. Date of Earliest Transaction  
(Month/Day/Year)  
06/06/20074. If Amendment, Date Original  
Filed(Month/Day/Year)  
06/08/20075. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)  
VP and Chief Scientific Off.6. Individual or Joint/Group Filing(Check  
Applicable Line)☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/06/2007		M	V 20,849 A \$ 0.43	2,928,214	D	
Common Stock	06/06/2007		F	849 D \$ 10.55	2,927,365	D	
Common Stock	06/06/2007		G	V 20,000 D \$ 0	2,907,365	D	
Common Stock	06/06/2007		S(1)	200 D \$ 10.5	2,907,165	D	

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4/A

Common Stock	06/06/2007	<u>S(1)</u>	1,000	D	\$ 10.51	2,906,165	D
Common Stock	06/06/2007	<u>S(1)</u>	500	D	\$ 10.52	2,905,665	D
Common Stock	06/06/2007	<u>S(1)</u>	1,400	D	\$ 10.53	2,904,265	D
Common Stock	06/06/2007	<u>S(1)</u>	3,100	D	\$ 10.54	2,901,165	D
Common Stock	06/06/2007	<u>S(1)</u>	2,097	D	\$ 10.55	2,899,068	D
Common Stock	06/06/2007	<u>S(1)</u>	1,102	D	\$ 10.56	2,897,966	D
Common Stock	06/06/2007	<u>S(1)</u>	2,403	D	\$ 10.57	2,895,563	D
Common Stock	06/06/2007	<u>S(1)</u>	3,453	D	\$ 10.58	2,892,110	D
Common Stock	06/06/2007	<u>S(1)</u>	2,200	D	\$ 10.59	2,889,910	D
Common Stock	06/06/2007	<u>S(1)</u>	442	D	\$ 10.6	2,889,468	D
Common Stock	06/06/2007	<u>S(1)</u>	200	D	\$ 10.62	2,889,268	D
Common Stock	06/06/2007	<u>S(1)</u>	100	D	\$ 10.63	2,889,168	D
Common Stock	06/06/2007	<u>S(1)</u>	100	D	\$ 10.66	2,889,068	D
Common Stock	06/06/2007	<u>S(1)</u>	800	D	\$ 10.67	2,888,268	D
Common Stock	06/06/2007	<u>S(1)</u>	300	D	\$ 10.7	2,887,968	D
Common Stock	06/06/2007	<u>S(1)</u>	3	D	\$ 10.72	2,887,965	D
Common Stock	06/06/2007	<u>S(1)</u>	600	D	\$ 10.77	2,887,365	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

# Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4/A

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	\$ 0.43	06/06/2007		M		20,849		01/01/2006	11/11/2008	Common Stock	20,849

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Frost Gregory Ian C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY ROAD, SUITE 17 SAN DIEGO, CA 92121	X VP and Chief Scientific Off.

## Signatures

/s/ Gregory Ian  
Frost 06/08/2007

\_\_Signature of  
Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares purchased and sold, as applicable, under 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.